Cosmos Health Inc. (Nasdaq: COSM) is a global healthcare group that was incorporated in 2009 and is headquartered in Chicago, Illinois. Cosmos Health is engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranation." Additionally, the Company is operating in the pharmaceutical sector through the provision of a broad line of branded generics and OTC medications and is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Health is strategically focused on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products. Cosmos has developed a global distribution platform and is currently expanding throughout Europe, Asia and North America. Cosmos Health has offices and distribution centers in Thessaloniki and Athens, Greece and Harlow, UK. More information is available at www.cosmoshealthinc.com and www.skypremiumlife.com.
Company profile
Ticker
COSM
Exchange
Website
CEO
Grigorios Siokas
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cosmos Holdings Inc., PRIME ESTATES & DEVELOPMENTS INC
SEC CIK
Corporate docs
Subsidiaries
Cosmofarm Ltd. • SkyPharm, S.A. • Decahedron Ltd. ...
IRS number
270611758
COSM stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
28 Nov 23
8-K
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
22 Nov 23
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
COSMOS HEALTH CEO Issues Letter to Shareholders
10 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Oct 23
8-K
Departure of Directors or Certain Officers
22 Sep 23
8-K
Other Events
14 Sep 23
DEF 14A
Definitive proxy
5 Sep 23
EFFECT
Notice of effectiveness
1 Sep 23
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm | 2.36 mm |
| Cash burn (monthly) | (no burn) | (no burn) | 1.14 mm | 1.60 mm | 1.51 mm | 2.24 mm |
| Cash used (since last report) | n/a | n/a | 2.43 mm | 3.41 mm | 3.22 mm | 4.79 mm |
| Cash remaining | n/a | n/a | -71.34 k | -1.05 mm | -860.78 k | -2.43 mm |
| Runway (months of cash) | n/a | n/a | -0.1 | -0.7 | -0.6 | -1.1 |
Institutional ownership, Q2 2023
5.5% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 14 |
| Opened positions | 11 |
| Closed positions | 2 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 2.02 bn |
| Total shares | 734.48 k |
| Total puts | 0.00 |
| Total calls | 400.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 291.91 k | $872.82 mm |
| Geode Capital Management | 95.11 k | $284.38 mm |
| Belvedere Trading | 89.38 k | $267.25 mm |
| Simplex Trading | 57.45 k | $171.00 k |
| Sabby Management | 35.01 k | $104.67 mm |
| Group One Trading | 33.39 k | $99.82 mm |
| Susquehanna International | 31.61 k | $94.51 mm |
| BAC Bank Of America | 25.11 k | $75.06 mm |
| STT State Street | 21.34 k | $63.82 mm |
| NTRS Northern Trust | 20.55 k | $61.46 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 Oct 23 | Georgios Terzis | Common Stock, $.001 par value | Grant | Acquire A | No | No | 1.01 | 51,485 | 52.00 k | 152,459 |
| 12 Oct 23 | Siokas Grigorios | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 23.66 | 6,712 | 158.81 k | 1,334,597 |
| 20 Jul 23 | Siokas Grigorios | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 2.48 | 181,451 | 450.00 k | 1,327,885 |
| 6 Jun 23 | Siokas Grigorios | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 23.92 | 4,474 | 107.02 k | 1,146,434 |
News
Cosmos Health Announces Patent Filing For Its Obesity And Weight Management Product
1 Dec 23
Cosmos Health Q3 EPS $(0.27) Up From $(1.93) YoY, Sales $12.82M Up From $12.02M YoY
21 Nov 23
Cosmos Health Reiterates 2026 Guidance Of Gross Annual Revenue Over $180M And Annual EBITDA Exceeding $20M
21 Nov 23
Cosmos Health Total Stockholders' Equity Increased By ~$5M To $44.2M Versus $39.3M In Dec 2022
21 Nov 23
Cosmos Health Q3 Sales $12.82M Up From $12.02M YoY
21 Nov 23
Press releases
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product
1 Dec 23
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share
21 Nov 23
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders
11 Oct 23
COSMOS HEALTH CEO Issues Letter to Shareholders
5 Oct 23
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
27 Sep 23